Page 1

Alterity THERAPEUTICS Appendix 4C - Q3 FY21 Quarterly Cash Flow Report Highlights : ● Michael J. Fox Foundation grants Alterity $ US495K for Parkinson's disease research evaluation Strengthening profile at investment , scientific and clinical conferences • Dr David Stamler appointed Chief Executive Officer • Cash balance as at 31 March 2021 of A $ 32.8M MELBOURNE , AUSTRALIA AND SAN FRANCISCO , USA 29th April 2021. Alterity Therapeutics Limited ( ASX : ATH , NASDAQ : ATHE ) ( " Alterity " or " the Company " ) releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2021 ( Q3 FY21 ) . The company's cash position was $ 32.8M with operational cash outflows of $ 5.1M , in line with company expectations and reflecting ongoing preparation for the Phase 2 clinical trial for Alterity's lead drug candidate ATH434 in Multiple System Atrophy ( MSA ) patients . In accordance with ASX Listing Rule 4.7C , payments made to related parties and their associates included at item 6.1 of the Appendix 4C incorporates directors ' fees , consulting fees , remuneration and superannuation at commercial rates . Operational Activities During the quarter , Alterity continued to make important advances in its Phase 2 program . Most of the company's efforts were focused on the bioMUSE Natural History study in MSA patients being conducted at Vanderbilt University Medical Center . This study will provide important information and insights to inform patient selection and design of the Phase 2 trial , which is scheduled to begin later this year . The study has now recruited 80 % of the original target population and the company is evaluating the feasibility to expand enrollment . The Michael J. Fox Foundation awarded Alterity US $ 495,000 to evaluate the pharmacologic profile of ATH434 to determine the optimal dose of the drug in future Parkinson's disease clinical trials . It was the second grant the company has received from the Michael J. Fox Foundation for ATH434 . The profile of Alterity continues to strengthen with the company regularly invited to present at investor conferences and the leading clinical and scientific events around the world . In January and then again in March , Alterity CEO Dr David Stamler presented at life science and healthcare conferences hosted by HC Wainwright attended by institutional fund managers , HNW and other investors . Alterity also participated in the Biotech Showcase , a satellite event at the world's largest healthcare conference hosted by JP Morgan . In February , the company presented at the 7th Annual International Congress of Multiple System Atrophy , the pre - eminent conference for scientists and clinicians focused on MSA . Alterity's presentation featured as part of the Congress ' poster presentation and provided further data on ATH434 . The new results included data on blood pressure following change in body position which demonstrated that ATH434 does not lower blood pressure when people move to the standing position . This is an important safety finding considering impaired maintenance of blood pressure is a key issue with MSA .